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The factor H–related protein family (CFHR)
is a group of minor plasma proteins genet-
ically and structurally related to comple-
ment factor H (fH). Notably, deficiency of
CFHR1/CFHR3 associates with protec-
tion against age-related macular degen-
eration and with the presence of anti-fH
autoantibodies in atypical hemolytic ure-
mic syndrome (aHUS). We have devel-
oped a proteomics strategy to analyze the
CFHR proteins in plasma samples from
controls, patients with aHUS, and pa-
tients with type II membranoproliferative
glomerulonephritis. Here, we report on
the identification of persons carrying
novel deficiencies of CFHR1, CFHR3, and
CFHR1/CFHR4A, resulting from point mu-
tations in CFHR1 and CFHR3 or from a
rearrangement involving CFHR1 and
CFHR4. Remarkably, patients with aHUS
lacking CFHR1, but not those lacking
CFHR3, present anti-fH autoantibodies,
suggesting that generation of these anti-
bodies is specifically related to CFHR1
deficiency. We also report the character-
ization of a novel CFHR1 polymorphism,
resulting from a gene conversion event
between CFH and CFHR1, which strongly
associates with aHUS. The risk allotype
CFHR1*B, with greater sequence similar-
ity to fH, may compete with fH, decreas-
ing protection of cellular surfaces against
complement damage. In summary, our
comprehensive analyses of the CFHR pro-
teins have improved our understanding
of these proteins and provided further
insights into aHUS pathogenesis. (Blood.
2009;114:4261-4271)
Introduction
The complement system is a major component of the innate
immune response to infection, and it is also involved in immuno-
complex removal and the destruction of damaged or anomalous
autologous cells. Improper complement activation is prevented by
several plasma and membranes proteins, which perform a regula-
tory, inhibitory function. Complement factor H (fH) is the main
inhibitor of the alternative pathway of the complement system.1
Deficiency or dysfunction of fH is associated with increased
susceptibility to infections and to chronic diseases such as atypical
hemolytic uremic syndrome (aHUS), type II membranoprolifera-
tive glomerulonephritis/dense deposits disease (MPGN2/DDD),
and age-related macular degeneration (AMD).2,3
The fH gene, CFH, spans approximately 100 kb (kilobases) in
the RCA (regulators of complement activation) gene cluster on
human chromosome 1q32.4 fH is a single polypeptide chain
glycoprotein of 155 kDa composed of 20 repetitive units of
60 amino acids named short consensus repeats (SCRs), which are
arranged in a continuous fashion. Alternative splicing of CFH
generates a shorter form of 43 kDa named fHlike-1 (CFHL1)
consisting of SCR1 to SCR7 plus an additional hydrophobic tail of
4 amino acids.5,6 In close proximity to CFH there are 5 genes
coding for proteins showing sequence and structural homology to
fH that are known as fH-related proteins (CFHRs).7 CFH and the
5 CFHR genes (CFHR1-5) lie in a head-to-tail arrangement and are
thought to have originated by successive duplication events within
the RCA gene cluster.8
The CFHR proteins were first identified by Western blot
analysis of human plasma with polyclonal anti-fH antibodies.9
They are all composed of SCR domains showing different degrees
of identity with the homologous domains in fH. The concentrations
of CFHR proteins in plasma are much lower than that of fH, and
their biologic function is currently unknown. Binding to the
physiologic fH ligand C3b has been reported for CFHR1, CFHR3,
CFHR4, and CFHR5,10-12 and C3 convertase regulatory activity has
been detected in CFHR5.13 Most recently, CFHR1 has been shown
to inhibit the C5 convertase and the membrane attack complex
formation,14 suggesting a sequential and complementary role for fH
and CFHR1 in complement regulation.
The CFH-CFHR1-5 genomic region includes several large
genomic duplications involving different exons of the CFH and
CFHR1-5 genes, which have mediated genomic rearrangements
through mechanisms of gene conversion and nonhomologous
recombination. Several examples of gene conversion events be-
tween exon 23 of CFH and the homologous exon 6 of CFHR1 have
been documented recently.8,15 Similarly, there is robust evidence of
major rearrangements in the CFH-CFHR1-5 gene region that result
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in the deletion of the CFHR1 and CFHR3 genes (CFHR1-CFHR3)16,17
and, occasionally, in the generation of CFH::CFHR1 hybrid
genes.18 These CFH-CFHR1-5 rearrangements can be easily identi-
fied by MLPA (multiplex ligation-dependent probe amplification)
technologies18 or by Western blot in the case of homozygote
carriers.17 Chromosomes carrying both the deletion of the CFHR1
and CFHR3 genes and a CFH::CFHR1 hybrid gene are rare and are
specifically associated with aHUS.18 In contrast, the deletion of the
CFHR1 and CFHR3 genes (CFHR1-CFHR3) without rearrangements
in CFH is a common genetic polymorphism that is associated with
a lower risk of AMD16,19 and with increased risk of aHUS because
of the generation of anti-fH autoantibodies.17,20,21 The rearrange-
ment that results in CFHR1-CFHR3 is not a recurring phenomenon but
a single event that became fixed in the human population a long
time ago.19 Additional genetic alterations within the CFH-
CFHR1-5 region are expected, and they probably have pathologic
implications. In this context, the characterization of the products of
CFH and CFHR1-CFHR5 genes would be most helpful.
We have characterized the CFHR proteins present in plasma
samples from control persons, patients with aHUS, and patients
with MPGN2/DDD by Western blot and have developed a strat-
egy based on the analysis of partially purified CFHR proteins
by 2-dimensional gel electrophoresis that increases resolution of
these proteins and shows novel structural features. Our results
improve our understanding of the genetic variability at the CFHR
region. They suggest a specific relationship between the defi-
ciency of CFHR1 and the generation of anti-fH autoantibodies
and show a novel polymorphism in CFHR1 that confers increased
risk to aHUS, thus providing further insights into the pathogene-
sis of aHUS.
Methods
Samples from patient and control persons
Blood samples were drawn from 151 patients with a clinical diagnosis of
aHUS and from 13 patients with MPGN2/DDD. Serum and EDTA-plasma
aliquots were stored immediately at 80°C until used. Peripheral blood
leukocytes were used to prepare genomic DNA. All samples were obtained
in the context of research studies on HUS and MPGN2/DDD that have the
approval of the Ethics Committee from the University Hospital La Paz.
Written informed consent was obtained from patients or their relatives in
accordance with the Declaration of Helsinki. A previously described cohort
of 141 patients with AMD22 was also included in some genetic studies as a
disease control group.
Blood samples were also drawn from a total of 105 control persons
(59 women and 46 men). Sixty-eight controls were healthy adult volunteers
(aged 21-73 years; median, 34 years); 37 controls were anonymous children
(aged 2-16 years; median, 6 years) who were about to undergo posttrau-
matic surgery in University Hospital La Paz but did not present signs of any
infectious-related condition. Serum, EDTA-plasma, and DNA were ob-
tained from these control samples, which were used for Western blot and
genetic analyses. DNA samples from other 125 control persons22 were also
available for some genetic studies.
Detection of fH autoantibodies in serum samples
Factor H autoantibodies in serum samples were detected with an enzyme-
linked immunosorbent assay following the method previously described by
Dragon-Durey et al.23 PBS (phosphate-buffered saline; pH 7.2) was used as
the coupling buffer, PBS-Tween (0.1% Tween 20) was used for washing
and blocking, and PBS-BSA (0.1% BSA) was used for preparing serum
dilutions. Ninety-six–-well microtiter plates (Immuno Plates MaxiSorp;
Nalge Nunc International) were coated overnight at 4°C with 0.2 g of
in-house purified fH24 in 100 L of PBS. After washing and blocking, serial
dilutions (1/100, 1/200, 1/400) of serum samples in PBS-BSA were added
in duplicate and incubated at 4°C overnight. The plates were washed again,
and 100 L of HRP-goat anti–human IgGs (Nordic Immunology) diluted
1/2500 in PBS-Tween was added. The enzymatic reaction was developed
with the peroxidase substrate ABTS (Roche Diagnostics GmbH). Absor-
bance values at 405 nm were compared with a reference positive sample,
provided by Dr Marie Agnes Dragon-Durey (Hoˆpital Georges Pompidou,
Paris, France), that had been given an arbitrary titer of 2000 AU/mL.
Samples above 150 AU/mL (mean  2 SDs obtained from 54 control
samples) were considered positive.
Heparin-sepharose chromatography
Factor H, CFHL1, and CFHR proteins were partially purified by affinity
chromatography on heparin-sepharose (GE Healthcare Bio-Sciences).
Serum samples were dialyzed at 4°C against 20mM Tris-HCl pH 7.5,
containing 50mM NaCl (equilibrating buffer). Dialyzed sera were incu-
bated overnight at 4°C with heparin-sepharose beads. Beads were then
centrifuged, and the supernatant was stored for further analysis. After
several washes in equilibrating buffer, bound proteins were eluted with
20mM Tris-HCl pH 7.5, 500mM NaCl.
Two-dimensional electrophoresis
Isoelectrofocusing (IEF) was used in the first dimension, and standard
SDS–polyacrylamide gel electrophoresis (PAGE) was used in the second
dimension. For IEF, immobilized pH gradient (IPG) strips of 7 cm and
different pH linear range were used (pH 3-10 or pH 4-7, Immobiline-
Drystrips, GE Healthcare; pH 5-8, ReadyStrips, Bio-Rad). Samples were
resuspended in IEF buffer (0.5% IPG buffer, 8 M urea, 2% Chaps, 0.002%
bromophenol blue) and loaded onto the IPG strips manually. IPG strips
were rehydrated at 20°C for 15 hours at 50 V, for 1 hour at 100 V, and for
1 hour at 1000 V in an IPGphor I horizontal apparatus (GE Healthcare). IEF
was carried out at 5000 V for 5 hours 30 minutes. IPG strips were
equilibrated in 50mM Tris-HCl, pH 6.8 buffer, containing 6M urea, 87%
glycerol, 2% SDS, 0.002% bromophenol blue. For the second dimension,
equilibrated IPG strips were placed on top of a 5% stacking–10% resolving
polyacrylamide minigel, and electrophoresed in the following conditions:
50 mA/30 minutes plus 75 mA/30 minutes plus 100 mA/90 minutes.
After electrophoresis, gels were either stained with Coomassie Brilliant
Blue G-250 (USB Corporation) for mass spectrometry (Proteomics Unit,
Universidad Complutense, Madrid, Spain) or processed for Western
blot analysis.
Table 1. Probes for MLPA analysis of the CFH-CFHR1-5 region
Probe Hybridizing sequence (5 to 3)
CFHex5L GGGAATACCATTTTGGACAAGCAGTACG
CFHex5R GTTTGTATGTAACTCAGGCTACAAGATTGAAGG
CFHex23L TGGACAGCCAAACAGAAGCTTTATTC
CFHex23RCFHR1ex6R GAGAACAGGTGAATCAGYTGAATTTG
CFHR1ex6L GGACAGCCAAACAGAAGCTTTATTT
CFHR1ex2L GTAATAGAAAACTTCCCCTGTAGGAACC
CFHR1ex2R TGGGAAAATGGCTTATATTTTTCTTCATC
CFHR2ex5L CCAACAAAATCTCATTCATTTCGAGCAAT
CFHR2ex5R GTGTCAGAATGGGAAACTGGTATATCCCAG
CFHR3ex6L AGCATTGTTACCCTAAATGTATGTCCAACTTC
CFHR3ex6R CACTTTTCCACTTCTCACTCTTATGGTCTCA
CFHR4ex4L GCACACACTGATTGGTAAATTTTATCCCTACAATG
CFHR4ex4R GGACTTTCTTAGTTGAGTTGTGCATCGTATG
CFHR5ex5L CGGGCCTAAGAAAATACAATGTGTGGATG
CFHR5ex5R GAGAATGGACAACTTTACCCACTTGTGTTG
MORF4L1ex9L GATGCTCCATAACTTAGAATGG
MORF4L1ex9R GGTTACATCGCAATAAACCCAG
BCAP31ex6L ACAGGAGCCTGAAGGCTGACCT
BCAP31ex6R GCAGAAGCTAAAGGACGAGCTGG
Reverse probes (R) were 5-phosphorylated.
4262 ABARRATEGUI-GARRIDO et al BLOOD, 5 NOVEMBER 2009  VOLUME 114, NUMBER 19
For personal use only.on June 4, 2016. by guest  www.bloodjournal.orgFrom 
Western blot analysis
Proteins were transferred to nitrocellulose membranes at 100 V for 1 hour
in a Mini Trans-Blot Cell apparatus (Bio-Rad). Membranes were blocked in
ECL (electrochemiluminescence) Advance blocking agent (GE Healthcare)
and incubated with primary antibodies for 2 hours. HRP-conjugated goat
anti–rabbit or anti–mouse IgG (Bio-Source; Invitrogen) was used as
secondary antibodies, and the membranes were developed with a chemilu-
minescent substrate (ECL Advance Kit; GE Healthcare) following the
manufacturer’s instructions.
Description of primary antibodies
Polyclonal antibodies were raised in rabbits. Antibody CFHR1 was
generated in the laboratory and recognizes fH, CFHL1, and the 2 iso-
forms of CFHR1: CFHR1 (37 kDa) and CFHR1 (43 kDa), containing
1 and 2 carbohydrate molecules, respectively.25 Antibody CFHR3/4
was provided by Prof Peter Zipfel (Hans-Kno¨ll Institute, Jena, Germany).
This antibody recognizes fH, CFHL1, CFHR3, and the 2 products of the
CFHR4 gene26: CFHR4A (86 kDa) and CFHR4B (46 kDa). Antibody
CFHR5 recognizes CFHR5 (65 kDa) and, to a lesser extent, fH, CFHR1,
and CFHR1; this was provided by Dr Jennifer McRae (St Vincent’s
Health, Melbourne, Australia). The monoclonal antibody 35H9 recognizes
fH and CFHL1 and has been described previously.27 Working dilutions of
the antibodies were 1:10 000 (MoAb 35H9), 1:50 000 (CFHR1), 1:30 000
(CFHR3/4), and 1:100000 (CFHR5).
Genetic studies
Rearrangements in the CFH-CFHR1-5 genomic region were analyzed by
MLPA. Copy number variations of CFHR1 and CFHR3 were determined
by using the P236 A1 ARMD mix 1 from MRC-Holland. Because this mix
does not include probes for the CFHR4 gene, another MLPA reaction was
designed with probes for specific exons of CFH and the 5 CFHR genes.
These probes were synthesized by Sigma-Aldrich and also included control
probes for the BCAP31 gene, located on chromosome X, and for the
MORF4L1 gene, located on chromosome 15. The hybridization sequences
are shown in Table 1. Each probe pair hybridized to sequences immediately
adjacent to the target region; the 3 probes (R) were 5-phosphorylated to
provide a free phosphate for the ligation reaction. A nonspecific sequence
between the hybridizing nucleotides and the nucleotides recognizing the
primers was introduced to adjust the length of the fragments. The reagents
for the MLPA reactions were purchased from MRC-Holland, and the
reaction was carried out following the manufacturer’s protocol. Two
microliters of the final product plus 0.2 L of internal standard (500LIZ)
and 10 L of deionized formamide (ABI no. 4311320) were analyzed in an
ABI-3730 DNAAnalyzer (Applied Biosystems).
All CFHR1 and CFHR3 exons were amplified by polymerase chain
reaction (PCR) with the use of specific oligonucleotides (Table 2). Direct
sequencing of the PCR products was performed with the use of the BigDye
Terminator Version 1.1 sequencing kit (Applied Biosystems) on an ABI
Prism 3100-Avant Genetic Analyzer.
Results
Identification of CFHR protein deficiencies by Western blot
Serum samples from 115 control persons, 149 patients with aHUS,
and 13 patients with MPGN2/DDD were analyzed by SDS-PAGE
and Western blot with 3 polyclonal antibodies that recognize fH, its
alternative splicing product, CFHL1, and the CFHR1-5 proteins.
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Figure 1. Identification of CFHR proteins deficiencies in serum samples. Serum samples from control persons, patients with aHUS, and patients with GN were analyzed
by SDS-PAGE and Western blot analysis by using 3 different antibody preparations (A-C) that recognize fH and CFHR proteins. Labels on the top of each gel refer to the
5 CFHR patterns observed: the most frequent pattern in which all the CFHR proteins analyzed are present (Normal), and 4 additional patterns showing different CFHR
deficiencies (DefR1R3, DefR1, DefR1R4A, and DefR3). The serum samples chosen to illustrate the 5 patterns correspond to the control sample C1 and to the patients with
aHUS H13, H119, H177, and H123, respectively. The position and size (kDa) of the molecular weight markers are shown to the left of gel A. The lane showing the DefR3 pattern
in panel C has been repositioned.
Table 2. Oligonucleotides for direct sequencing of CFHR1 and CFHR3 genes
Exon Domain Forward primer (5 to 3) Reverse primer (5 to 3) Size, bp
CFHR1ex1 SP GGACTTTACTAAACTAGCTTCCAG GCAACTTAGAGGATGGAGAG 400
CFHR1ex2 SCR1 TTATGTTATTTTCCCAGCAACAT AATGACATCCATTTAATGAACAGA 248
CFHR1ex3 SCR2 AAGCGCAGAGATTACCAGAG GATAACAGCATATGAGAGAACAG 330
CFHR1ex4 SCR3 CGTCTTGAAACATATTTGTAACTGTATT GGTCGAATCTTTCTCAAAAATAATAC 460
CFHR1ex5 SCR4 TGTATTTTGATTTGCTCTCACAAT GATTATTTTGTTACCAACAGCA 314
CFHR1ex6 SCR5 ATTTAAATCAATATGATGTTTTTACATAGTC CAGAAATAAAGTCTGAAAAATTGCA 703
CFHR3ex 1 SP CTAGCTTCATGGTAGTGCAC TTTAAGAGGGAAGCTGAGTG 220
CFHR3ex 2 SCR1 AAATGTTTGAGAGAAGGTGATATC TTTTTCATATGATTTTCAAGAACTC 472
CFHR3ex 3 SCR2 CATTTACTTTATTTATTTATCATTGCTATG TCTGAGACTGTCGTCCG 282
CFHR3ex 4 SCR3 CTTGTTCCCTCCTATAAAAGAAC GCAACTAACATATTTTGCTGATAC 547
CFHR3ex 5 SCR4 TTGAAAATGCAGATGTCTTCC GAACTCCTGACCTCATGG 604
CFHR3ex 6 SCR5 CATTTTATTTGCTCATGAAAGAG TTCATTGATAAGAAGTCCAATATAAGA 507
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As illustrated in Figure 1, 4 banding patterns showing different
CFHR proteins deficiencies were observed: deficiency of both
CFHR1 and CFHR3 (DefR1R3), isolated deficiency of CFHR1
(DefR1), isolated deficiency of CFHR3 (DefR3), and deficiency of
both CFHR1 and CFHR4A (DefR1R4A). Figure 1 also shows the
normal, most common situation in which all CFHR proteins are
present. The frequency of these complete CFHR deficiencies in
control persons, patients with aHUS, and patients with MPGN2/
DDD is shown in Table 3. In agreement with previous re-
ports,17,20,21 we found that DefR1R3, present in approximately 2%
of healthy controls, is associated with an increased risk of aHUS
(12 of 149 vs 2 of 115; P  .026; OR  4.95; 95% CI, 1.1-22.6)
and is particularly elevated among patients with autoantibodies
against fH (3 of 7 patients; see Table 7). Isolated deficiency of
CFHR1 (DefR1) or CFHR3 (DefR3), as well as combined CFHR1/
CFHR4A deficiency (DefR1R4A), were found only among patients
with aHUS and patients with MPGN2/DDD.
Genetic analysis of CFHR deficiencies
Deficiency of CFHR1/CFHR3. Genetic studies using specific
MLPA probes showed that all persons presenting the DefR1R3
pattern were homozygous for the 84-kb long genomic deletion
(CFHR1-CFHR3) previously described by Zipfel et al.17 Analysis of
this deletion was also carried out in additional control samples, as
well as in a previously described cohort of patients with AMD.22
The results are shown in Table 4. In agreement with previous
observations,16,19 we found that the CFHR1-CFHR3 deletion is a
protective factor for AMD. However, the CFHR1-CFHR3 allele
frequencies show no differences between control persons, patients
with aHUS, or patients with MPGN2/DDD; nonetheless, there is an
excess of CFHR1-CFHR3 homozygotes in the aHUS cohort that
significantly deviates from the expected value estimated from the
CFHR1-CFHR3 allele frequency. Thus, the aHUS population is not in
Hardy-Weinberg equilibrium for the CFHR1-CFHR3 polymorphism,
most probably because of the presence of patients with fH
autoantibodies (see “Discussion”).
Novel CFHR deficiencies. Analysis of the CFHR1-CFHR3 dele-
tion was also carried out in the 6 patients presenting the novel
CFHR deficiency patterns (DefR1, DefR3, and DefR1R4A). Addi-
tional MLPA analyses within the CFHR1-5 subregion of the RCA
gene cluster and direct sequencing of CFHR1 and CFHR3 genes
were also performed in these patients (see “Genetic studies” for
details). These studies identified novel genetic alterations associ-
ated with the CFHR deficiencies that are summarized in Table 5.
The 5 patients presenting CFHR1 or CFHR3 deficiency carry
CFHR1-CFHR3 in heterozygosis and therefore lack one CFHR1 allele
and one CFHR3 allele. Sequencing analyses of the CFHR1 gene
showed a heterozygous mutation in patient H119 that resulted in
the substitution of a serine for a stop codon at position 160 in the
SCR3 domain (c.479C 	 A; Ser160Stop; Figure 2A). This is a null
mutation that generates a truncated CFHR1 protein that is probably
not expressed. Similarly, sequencing analyses of all the exons and
the promoter region of the CFHR3 gene identified a heterozygous
mutation in patient H123 that results in the deletion of 2 nucleo-
tides in exon 6 (c.839_840delTA). This deletion causes a frameshift
mutation (p.I280KfsX6) that generates a stop codon 6 amino acids
downstream of position 280, at the beginning of the SCR5 domain
(Figure 2B). Mutation c.839_840delTA is therefore a null mutation
that generates a truncated CFHR3 protein most probably not
expressed. No mutations in CFHR3 were found in patients
H150 and GN11.
MLPA analysis in patients H177 (DefR1R4A) and GN9 (DefR1)
resulted in the identification of a novel rearrangement that specifi-
cally removes the CFHR1 and CFHR4 genes (Figure 3A). We refer
to this deletion as CFHR1-CFHR4, and it probably involves a
nonhomologous recombination event in the 3 regions of the
CFHR3 and CFHR4 genes. Patient H177, lacking both CFHR1 and
CFHR4, is homozygous for this rearrangement, whereas patient
GN9, lacking only CFHR1, is a compound heterozygote for
CFHR1-CFHR4 and CFHR1-CFHR3 (Figure 3B). Further analysis of all
the persons in our aHUS, MPGN2/DDD, and control cohorts
identified the presence of this heterozygous rearrangement in some
additional persons (Figure 3C), showing that CFHR1-CFHR4 is a
polymorphic trait in humans, although probably less frequent
than CFHR1-CFHR3.
CFHR protein deficiencies in patients with aHUS with anti-fH
autoantibodies
Serum samples from control persons, patients with aHUS, and
patients with MPGNII/DDD were screened for the presence of
Table 4. Allelic frequency of CFHR1-CFHR3 in patients and controls
n CFHR1-CFHR3 OR (95% CI)
Homozygotes CFHR1-CFHR3
observed vs expected
Hardly-Weinberg
equilibrium
Controls
Aged 0-30 y 135 24.1 NS 7 vs 8 NS
Aged 30-60 y 43 25.58 NS 2 vs 3 NS
Aged older than 60 y 92 24.72 NS 6 vs 6 NS
Totals 269 24.53 NS 15 vs 16 NS
AMD patients 141 9,6 0.29 (0.181-0.475)* 2 vs 1 NS
aHUS patients 137 21.12† NS 14 vs 6‡ 0.00015
MPGN2 patients 11 18 NS 0 vs 0 NS
NS indicates not significant.
*P 
 .001.
†The CFHR1-CFHR3 allele frequency is not increased in aHUS compared with controls (21.12 vs 24.53).
‡The frequency of CFHR1-CFHR3 homozygotes in aHUS is significantly higher than that expected from the CFHR1-CFHR3 allele frequency. There is also an increase in the
frequency of CFHR1-CFHR3 homozygotes in aHUS compared with controls (14 of 137 compared with 15 of 269), which does not reach statistical significance probably because of
the size of our cohorts.
Table 3. Patterns of CFHR proteins as observed by Western blot
analysis
Pattern Controls (n  115) aHUS (n  149) MPGN2/DDD (n  13)
Normal 113 133 9
Def R1R3 2 12 2
Def R1 0 1 1
Def R3 0 2 1
Def R1R4A 0 1 0
4264 ABARRATEGUI-GARRIDO et al BLOOD, 5 NOVEMBER 2009  VOLUME 114, NUMBER 19
For personal use only.on June 4, 2016. by guest  www.bloodjournal.orgFrom 
anti-fH autoantibodies basically as described.23 Autoantibodies
were only detected in 7 pediatric patients with aHUS. The
autoantibody titer and the main complement findings in the first
serum sample available from these patients are shown in Table 6.
Additional data on plasma treatment and renal function are also
included in this table. Characterization of CFHR proteins by
Western blot showed distinct CFHR deficiencies in 5 of these
7 patients (Table 7). Combined deficiency of both CFHR1 and
CFHR3 was observed in only 3 patients (H87, H108, and H154),
who were homozygous for the CFHR1-CFHR3 deletion. Deficiency of
CFHR1 and CFHR4A was observed in 1 patient (H177), presenting
homozygous CFHR1-CFHR4 deletion. Finally, a single deficiency of
CFHR1 was detected in another patient (H119) who was a
compound heterozygote for the CFHR1-CFHR3 deletion and a mis-
sense mutation in the CFHR1 gene. Therefore, 5 of the 7 patients
with fH autoantibodies showed homozygous CFHR1 deficiency,
but the underlying genetic defects differ between the patients.
Importantly, none of the patients presented mutations in the CFH,
CFI, CFB, C3, or MCP genes.
Two-dimensional analysis of CFHR proteins
The analysis of serum samples by monodimensional electrophore-
sis and Western blot allowed detection of all products of CFH and
CFHR genes thus far described. However, the bands corresponding
to CFHR3 and CFHR4B overlap and could not be properly
resolved. A similar situation was observed with CFHR1 and
CFHL1. To solve these difficulties and to properly character-
ize these proteins, we performed 2-dimensional electrophoresis
(2-DE), using IEF in the first dimension and SDS-PAGE in the
second dimension.
Affinity chromatography on heparin-sepharose at low ionic
strength (50mM NaCl) was used to remove major serum compo-
nents (albumin and immunoglobulins) interfering with the 2D-gel
analysis and to enrich the fH and CFHRs preparations.
The 2D-gel analysis of a normal control sample (C1) shows that fH
and the CFHR proteins present complex patterns, including several
isoforms (Figure 4A 2-DE). Isoform patterns corresponding to fH,
CFHR4A, and CFHR5 were identified based on their molecular
weights. Isoform patterns corresponding to CFHR1, CFHL1, CFHR3,
and CFHR4B were assigned by comparison with the 2D-gels obtained
from serum samples of patients with aHUS with complete deficiencies
of CFHR1 or CFHR3 or both (Figure 4B). Differences between the
theoretical and the observed isoelectric points were evident for most of
the CFHR proteins (Figure 4A), suggesting the existence of posttransla-
tional modifications that attached charged residues to the carbohydrate
molecules of these proteins.
To determine whether the isoform patterns of the CFHR
proteins remained constant in different persons, we analyzed
Table 5. Genetic alterations in patients with novel CFHR deficiencies
Patient Deficiency CFHR1-CFHR3 CFHR1-CFHR4 CFHR1 mutation CFHR3 mutation
H119* DefR1 Heterozygosis No Heterozygosis No
GN9 DefR1 Heterozygosis Heterozygosis No No
H177* DefR1R4A No Homozygosis No No
H123 DefR3 Heterozygosis No No Heterozygosis
H150 DefR3 Heterozygosis No No No
GN11 DefR3 Heterozygosis No No No
H119, H177, H123, H150 are patients with aHUS. GN9 and GN11 are patients with MPGN2/DDD.
*Patient with aHUS with anti-fH autoantibodies.
CFHR3
CFHR1
c.479 C>A 
( p.160 S>Stop)
A
Patient H123
Patient H119
T    A    G    T    G    T   A     G    A   G   A   C   A    G
A A    T A A C A    A A    G     T     T A     A
Control
Control
T    A     G   T    G    T    C  G   A   G   A   C   A    G
A    T A A C A    T A     A     A G T    T A
B
c.839_840delTA
p.I280KfsX6
Figure 2. Genetic analysis of CFHR1 and CFHR3 genes. Electropherograms showing the mutations identified in patients with aHUS (A) H119 (CFHR1 gene) and (B) H123
(CFHR3 gene). The 2 mutations were found in heterozygosis. The mutation in patient H123 could also be interpreted as c.838_839delAT (p.I280KfsX6). SwissProt accession
numbers for protein sequences are Q03591 (CFHR1) and Q02985 (CFHR3). Nucleotide numbering is based on the translation start site; A in ATG is1.
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6 additional control persons (samples C2 to C7) and a “pooled”
sample, including the 7 controls (sample P). All samples were
analyzed by using IPG strips of 3 pH ranges to optimize isoform
resolution of the different CFHR proteins.
Good separation of CFHR3 and CFHR4B by 2-DE was
achieved by using IPG strips in the pH range of 3 to 10 (Figure 5A).
Both proteins present a ladder pattern, but CFHR3 isoforms are
more acidic, with an estimated pI range of 4.5 to 6, whereas
CFHR4B isoforms are in the pI range of 6 to 7. Resolution of
CFHR3 isoforms improves when using IPG strips in the pH range
of 4 to 7. The patterns obtained in the 7 control persons and in the
pooled control sample analyzed were very similar, with a total of
8 isoforms differing in both pI and molecular weight (Figure 5B).
This isoform distribution explains the broad CFHR3 band observed
by monodimensional analysis (Figure 4A lane 1DE). A single
CFHR4B pattern was also apparent from the analysis of the same
control samples (Figure 5B). A total of 5 isoforms with different pI
and molecular weight were observed in all control samples
analyzed, although the relative expression of the isoforms varied.
Resolution of the CFHR1/CFHL1 region was improved by using
IPG strips with pH 5 to 8 in the IEF step, 10% SDS-PAGE in the second
dimension, and Western blot with a monoclonal antibody that recog-
nizes CFHL1 but not CFHR1. These conditions allowed proper
identification of protein spots in the region, permitting discrimination
between CFHL1 and CFHR1 isoforms. As shown in Figure 6A,
2 CFHL1 isoforms differing in molecular weight and pI were detected in
the control sample analyzed. The minor isoform, partially overlapping
with one of the CFHR1 isoforms, cannot be easily appreciated with the
use of IPG strips in the pH range of 3 to 10 (Figure 4A). To confirm that
the spots in the region assigned to CFHR1 isoforms indeed correspond
to CFHR1, a replicate gel was stained with Coomassie Brilliant Blue
G-250, and the spots matching those in the Western blot shown in Figure
6A were picked up manually and analyzed by peptide mass fingerprint-
ing. All these spots were identified as CFHR1 (Swiss Protein Database
entry Q03591).28
Interestingly, among the 7 control persons analyzed in this
report, 3 distinct patterns of CFHR1 isoforms were identified
(Figure 6B). Pattern A (Acidic), composed of 2 CFHR1 isoforms
Table 6. Clinical and complement data in patients with aHUS with anti-fH autoantibodies
Patient
HUS onset First serum sample analyzed
Current age and
situation
Age,
y
Plasma
therapy
Renal
function
Time after
onset
AutoAb titer,
AU/mL*
C3,
mg/dL*
C4,
mg/dL*
CFH,
mg/dL*
H87 5 PE Full recovery Onset 600 55.7† 8.85† 25 11 y; unknown
H108 4 PE Full recovery 3 mo 1600 86.2 28.4 22 8 y; ESRD
H119 4 None ESRD 13 y 600 117 16.6 28 20 y; RT since 1995
H151 6 PE  PI Full recovery 7 mo 6000 66.7† 16.7 31 8 y; stable with corticoids
H154 8 PE Full recovery Onset 18 000 58.5† 19.6 26 10 y; stable with azathioprine
H171 3 None ESRD 5 mo 3600 81.3 40.6 25 4 y; RT since March 2009
H177 7 PF  5% albumin Death (myocarditis) Onset 16 000 58.5† 19.6 22 Died during first episode
PE indicates plasma exchange; PF, plasmapheresis; PI, plasma infusion; ESRD, end-stage renal disease; and RT, renal transplant.
*Normal values: AutoAb titer,
 150 AU/mL; C3, 77-135 mg/dL; C4, 14-47 mg/dL; CFH, 12-56 mg/dL.
†Value out of normal range.
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FHR 3 FHR 4FHR 1 FHR 2 FHR 5C FH
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Figure 3. Identification of CFHR1-CFHR4 deletion by MLPA. (A) Nonhomologous recombination event between homologous regions of the CFHR1 and CFHR4 genes that
could have resulted in the CFHR1-CFHR4 deletion. (B) Electropherograms of the MLPA analyses showing heterozygous and homozygous deletions in patients with aHUS.
(C) Frequency of the novel CFHR1-CFHR4 deletion in control persons and patients.
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and 5 CFHR isoforms, was characteristic of control persons C3
and C4. Pattern B (Basic), also composed of 2 CFHR1 isoforms
and 5 CFHR isoforms but slightly more basic than those in pattern
A, was present in control samples C1, C2, and C6. Finally, pattern
AB contains all isoforms observed in patterns A and B (4  and
8 ); this pattern was observed in persons C5 and C7, and it was
also obtained in the pooled sample P. The 2 CFHL1 isoforms were
constant in the 7 control samples. The 3 CFHR1 isoform patterns
closely resemble the 3 phenotypes observed by Susukida et al29
when analyzing samples from healthy volunteers in a study on fH
polymorphism.
Genetic analysis of the CFHR1 A and B isoform patterns
The CFHR1 2D isoform patterns A, B, and AB were suggestive of a
polymorphism involving 2 allotypes, with patterns A and B as
homozygotes or hemizygotes for each allele, and pattern AB
corresponding to the heterozygote. To test this possibility, we
sequenced all coding exons of the CFHR1 gene in the 7 control
persons analyzed, and found that persons presenting pattern A and
pattern B differed in their nucleotide sequences at different
positions in exons 4, 5, and 6 (Figure 7A; supplemental figure,
available on the Blood website; see the Supplemental Materials
Table 7. CFHR deficiencies and genetic alterations in patients with aHUS with anti-fH autoantibodies
Patient CFHR1 deficiency CFHR3 deficiency CFHR4A deficiency CFHR1-CFHR3 CFHR1-CFHR4 CFHR1 mutation Other mutations*
H87 X X — Homozygote — — —
H108 X X — Homozygote — — —
H154 X X — Homozygote — — —
H177 X — X — Homozygote — —
H119 X — — Heterozygote — Heterozygote —
H151 — — — Heterozygote — — —
H171 — — — — — — —
X indicates homozygous deficiency; and —, no deficiency/no genetic alteration.
*Genes analyzed were CFH, MCP, CFI, CFB, and C3.
2DEpH3 pH10
1DE
CFHR3/CFHR4B
CFHR5
CFHR4A
CFH
CFHR1α
CFHR1β/CFHL1
A Control C1 (Normal CFHR pattern)
200
120
100
55
38
CFHR1β/CFHL1
CFHR1α
CFHR4BCFHR3
CFHR4A
CFH
CFHR5
B
Patient H123
(Def R3)
Control C1
(Normal)
Patient H13 
(Def R1R3)
2DE (pH 3-10)
55
38
55
38
CFHR4B
CFHL1
CFHR3
CFHR4B
CFHR1β/CFHL1
CFHR1α
2DE (pH 3-10)
Patient H119
(Def R1)
CFHR4B
CFHL1
CFHR4B
CFHR3
CFHR1α
CFHR1β/CFHL1
Figure 4. Analysis of CFHR proteins by 2-DE. (A) Western blots obtained after monodimensional (1DE) or 2-dimensional (2DE) electrophoresis of the heparin-sepharose
eluate corresponding to control person C1, showing the Normal CFHR pattern. A single antibody solution containing equivalent amounts of the individual CFHR1, CFHR3/4,
and CFHR5 antibody preparations was used. The position and size (in kDa) of molecular weight markers is also indicated. (B) Two-dimensional analysis of CFHR1/CFHL1
and CFHR3/CFHR4B isoforms in control sample C1 and in 3 patients with aHUS showing the CFHR patterns DefR1R3, DefR1, or DefR3. CFHR4B isoforms are surrounded by
dotted circles. Arrows indicate CFHL1 isoforms. The theoretical isoelectric points calculated with Compute pI/molecular weight program at ExPASy server (http://ca.expasy.org/
tools/pi_tool.html) were CFH (6.12), CFHL1 (6.77), CFHR1 (7.53), CFHR3 (7.79), CFHR4A (4.85), CFHR4B (5.16), and CFHR5 (6.87).
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link at the top of the online article). Three nucleotide differences in
CFHR1 exon 4 (c.469, c.475, and c.523) involve 3 amino acid
changes in the SCR3 domain of CFHR1 (Figure 7A). Persons
presenting pattern A were homozygotes or hemizygotes for a
CFHR1 allele carrying His157-Leu159-Glu175 (CFHR1*A), and per-
sons presenting pattern B were homozygotes or hemizygotes for a
second CFHR1 allele carrying Tyr157-Val159-Gln175 (CFHR1*B)
(Figure 7B). Interestingly, the nucleotide differences between the
CFHR1*A and CFHR1*B alleles, including those involved in
amino acid substitutions at positions p.157, p.159, and p.175, are
differences that distinguish exon 4 of CFHR1 from exon 21 of
CFH, respectively, suggesting that the CFHR1*B allele could have
originated by a gene conversion event between CFHR1 and CFH.
Sequencing analyses of the CFHR1 and CFH genes in 129 con-
trols and 151 patients with aHUS showed that the length of the gene
conversion fragment is restricted to a short DNA sequence included
within CFHR1 exon 4, which is internal to the primers used for
PCR amplification of this exon. The data are consistent with the
interpretation that this gene conversion event occurred a long time
ago. This novel polymorphism increases the genetic variability at
the CFHR1 gene, which should now be considered as a polymor-
phic locus, including 3 major alleles: CFHR1*A, CFHR1*B, and
CFHR1-CFHR3. The frequencies of these alleles in controls and
patients with aHUS are shown in Table 8. Notably, the frequency of
the CFHR1*B allele is significantly increased in the aHUS cohort,
suggesting that carriers of this CFHR1 variant have an increased
risk of developing aHUS. The analysis of the frequencies of the
different CFHR1 genotypes in controls and patients with aHUS
further showed that the association with aHUS is restricted to the
condition of homozygosity for the CFHR1*B allele (carriers of
2 CFHR1*B copies) (Table 8). These data unravel a novel risk
factor for aHUS and suggest that normal expression of the
CFHR1*B allotype, more similar to fH, may compete or interfere
with the normal function of fH, decreasing protection of cellular
surfaces from damage by complement.
Discussion
CFHR proteins are a group of minor plasma proteins that show
structural and genetic homology to fH.7 Evolution of this family
has resulted in genomic duplications that extend along the CFH-
CFHRs subregion of the RCA gene cluster,8 and are the basis for
the strong sequence similarity among fH and the CFHR proteins.
The presence of these duplicated regions, however, favors gene
conversion and nonhomologous recombination events that have
been associated to aHUS.3
We report here the use of one-dimensional and 2D gel
electrophoresis combined with Western blot analysis to analyze the
CFHR proteins in plasma samples from patients with aHUS and
patients with MPGN2/DDD. These analyses have resulted in the
identification of persons carrying 3 novel CFHR protein deficien-
cies, DefR1, DefR3, and DefR1R4A, and have shown a previously
unrecognized CFHR1 polymorphism. Genetic analysis in persons
pH 4.5 pH 6
CFHR3
pH 6 pH 7
1 2 3 4 5
6
7 8
Sample P
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Control C3
1
2
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5
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Figure 5. Characterization and variability of the CFHR3/CFHR4B region. (A) Separation of CFHR3/CFHR4B isoforms by 2DE. Western blot obtained with the
heparin-sepharose eluate from control persons C1 and the CFHR3/4 antibody preparation. (B) CFHR3 and (C) CFHR4B isoform patterns observed in individual samples (C2,
C3) or in the pooled-control sample (P). The pH range used in the IEF step is shown at the top of the gels, and a schematic representation of each pattern is shown at the
bottom.
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carrying these novel variations have shown that they have in part
been generated as a consequence of the genomic instability in this
region of the RCA gene cluster.
As expected from previous studies, DefR1R3 is the most
frequent deficiency of CFHR proteins in our control population and
in the patient cohorts. In agreement with previous results16 both the
allelic frequency of CFHR1-CFHR3 and the number of homozygotes
are significantly associated with protection from AMD in the
Spanish population (Table 4). In patients with aHUS, however,
we could not replicate previous reports17 indicating that the
CFHR1-CFHR3 allele is associated with an increased predisposition to
the disease; we found no differences between patients and controls
for the frequency of the CFHR1-CFHR3 allele. Importantly, our aHUS
population is out of Hardy-Weinberg equilibrium for the CFHR1
polymorphism because of an excess of CFHR1-CFHR3 homozygotes
(pattern DefR1R3). Therefore, we conclude that the reported
association of CFHR1-CFHR3 with increased risk to aHUS only holds
true for homozygous carriers.
A significant number ofCFHR1-CFHR3 homozygotes carry anti-fH
autoantibodies,20 but whether a deficiency of CFHR1/CFHR3 is
pathologically relevant or whether it is a marker for a different
genetic defect is currently unknown. An important finding in our
studies is the recognition that 2 patients with aHUS with anti-fH
autoantibodies presented homozygous deficiency of CFHR1 but
not of CFHR3 (Table 7). Moreover, the CFHR1 deficiency in these
2 patients was caused by a combination of different genetic defects.
Patient H119 is a compound heterozygote for CFHR1-CFHR3 and a
nonsense mutation in CFHR1 (p.160S 	 Stop), whereas patient
H177 is a homozygote for a novel genomic deletion involving the
CFHR1 and CFHR4 genes (CFHR1-CFHR4). Thus, among the
7 patients carrying anti-fH autoantibodies in our aHUS series,
5 of them presented a deficiency of CFHR1 as a consequence of
3 different genetic alterations. These data highlight a direct
relationship between the lack of CFHR1 and the presence of
anti-fH autoantibodies. They also suggest that the association of the
autoantibodies with the genomic deletion encompassing CFHR1
and CFHR3 (CFHR1-CFHR3) is secondary to this relationship. This
conclusion is further supported by the fact that only 3 of the
12 homozygous CFHR1-CFHR3 patients with aHUS develop anti-fH
autoantibodies. In addition, the 2 patients with a single CFHR3
deficiency were negative for the anti-fH autoantibodies.
There is no clear explanation for the association between the
deficiency of CFHR1 and the presence of anti-fH autoantibodies in
patients with aHUS. These autoantibodies have been reported to
recognize SCR19-SCR20 of fH,30 which are involved in binding to
glycosaminoglycans and surface-bound C3b.31 As shown in Figure
7B, these SCRs are nearly identical to SCR4-SCR5 of CFHR1, so it
is likely they can also recognize this protein. Unpublished data
from our group suggest that anti-fH autoantibodies from CFHR1-
deficient patients (patients H108, H154, and H177 in this report)
crossreact with CFHR1, whereas this crossreactivity was not
observed in the only patient with a normal CFHR1 expression that
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Figure 6. Characterization and variability of the CFHR1/CFHL1 region. (A) Two-dimensional electrophoretic analysis of the heparin-sepharose eluate obtained from control
person C1, followed by Western blot with a polyclonal antibody preparation recognizing CFHR1 and CFHL1, or with a monoclonal antibody specific for CFHL1. Only the gel
area corresponding to the CFHR1/CFHL1 region is shown. Spots numbered from 1 to 6 were picked up from a replicate gel stained with Coomassie and were identified as
CFHR1 by matrix-assisted laser desorption-ionization time-of-flight spectrometry in a 4700 Proteomics Analyzer (PerSeptives Biosystems). (B) CFHR1 isoforms observed
after 2DE and Western blot analysis of heparin-sepharose eluates from different control persons. C1 to C7 indicate individual samples; P, pooled-control sample. Isoforms
characteristic of patterns A or B are labeled. Arrows indicate CFHL1 isoforms. A scheme of the 3 isoform patterns observed is shown on the right. The molecular weights (kDa)
of the CFHR1 isoforms are indicated at the left.
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we could study (patient H151; C.A.-G. and P.S.-C., manuscript in
preparation). Therefore, the autoantibodies in persons expressing
CFHR1 may be different from those present in CFHR1-deficient
persons. We would like to suggest that autoantibodies generated in
the context of a CFHR1 deficiency are targeted to a region of the fH
molecule that is critical for the developing of aHUS.
The physiologic function of CFHR1 is beginning to be under-
stood. A recent report14 suggests CFHR1 has a complement
regulatory activity at the level of the alternative pathway C5
convertase and the lytic pathway, a function mediated through the
binding of the SCR1-SCR2 domains of CFHR1 to C5 and C5b6.
Moreover, CFHR1 would also compete with fH for C3b and
polyanionic binding on cell surfaces, thus interfering with the
complement regulatory activity of fH. This potential fH-CFHR1
functional interference on cellular surfaces relies on the strong
sequence similarity between SCR18 to SCR20 of fH and SCR3 to
SCR5 of CFHR1 and is supported by genetic data from patients
with aHUS.15,24
Characterization of CFHR1 by 2D gel electrophoresis and
Western blot analysis showed acidic and basic isoforms of this
protein in control persons (Figure 6). Genetic studies showed that
the acidic and basic isoforms are indeed 2 CFHR1 allotypes
(CFHR1*A and CFHR1*B) that differ in 3 amino acids within the
SCR3 domain. Interestingly, these 3 amino acid differences make
the SCR3 domain of the CFHR1*B allotype identical to the SCR18
domain of fH (Figure 7B). The 2 CFHR1 allotypes most probably
correspond to the 2 human liver cDNA clones previously de-
scribed,32 which were generated by a gene conversion event
between the CFHR1 and the CFH genes. We present here the
results of a case-control association study in the aHUS Spanish
cohort showing that CFHR1*B, the allele presenting the highest
sequence similarity to CFH, is strongly associated with increased
risk of aHUS when it is present in homozygosity (2 copies; Table
8). These are novel and interesting data that may reflect a
competition between CFHR1 and fH, decreasing the functional
activity of fH on surfaces and thus predisposing to complement-
mediated damage.
In conclusion, the analysis of CFHR proteins using 1- or
2-dimensional gel electrophoresis and Western blot analysis have
allowed us to explore additional variability in the CFH-CFHR1-5
genomic region, providing new structural data on these proteins.
For the first time, we have identified isolated deficiencies of
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Figure 7. Genetic basis for the 2D isoform patterns of CFHR1. (A) Electropherograms of CFHR1 exon 4 obtained from control persons presenting the CFHR1 2D isoform
patterns A, B, and AB, respectively. The 3 nucleotide differences involving amino acid changes that distinguish the CFHR1*A and CFHR1*B alleles (c.469, c.475, and c.523) are
shown. (B) Alignment of the homologous domains in CFHR1 (SCR3 to SCR5) and fH (SCR18 to SCR20). The amino acid differences between domains are indicated. SCR4 in
CFHR1 and SCR19 in fH are identical. CFHR1A and CFHR1B isoforms differ in 3 amino acid residues located in the SCR3 domain (p.157, p.159, p.175); the theoretical pI is
shown in brackets. The SCR3 domain in CFHR1B is identical to the SCR18 domain in fH. SwissProt accession numbers for protein sequences are Q03591 (CFHR1) and
P08603 (fH). Nucleotide numbering is based on the translation start site: A in ATG is1.
Table 8. CFHR1 allele frequencies and genotype frequencies in
aHUS association studies
Frequencies*
P OR (95% CI)
Controls
(n  129)
aHUS
(n  151)
Allele
(A) CFHR1*A 0.37 0.30
(B) CFHR1*B 0.39 0.48 .033 1.46 (1.04-2.04)
(Del) CFHR1-CFHR3 0.24 0.22
Genotype
A/A 0.15 (19) 0.13 (19)
B/B 0.13 (17) 0.28 (42) .003 2.54 (1.36-4.73)
Del/Del 0.07 (9) 0.11 (16)
A/Del 0.14 (18) 0.09 (13)
B/Del 0.20 (26) 0.15 (22)
A/B 0.31 (40) 0.26 (39)
*Numbers in parentheses indicate number of participants in study.
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CFHR1 and CFHR3, and established a specific relationship
between the CFHR1 deficiency and the generation of anti-fH
autoantibodies associated with aHUS. The discovery of a common
CFHR1 allotype, which is associated with an increased risk of
aHUS, is an exciting finding that may unravel a functional
interference between CFHR1 and fH with consequences in pathol-
ogy. These novel data warrant new studies that, in addition to
increasing our understanding of the CFHR proteins, will probably
improve our knowledge of the pathogenic mechanisms in aHUS.
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